5-Amino-1MQ vs SLU-PP-332 vs AICAR: the difference explained

Research context (RUO): this page compares three metabolic research compounds on the basis of published preclinical research. The information is intended exclusively for in vitro research and does not constitute medical advice or instructions for use.

5-Amino-1MQ vs SLU-PP-332 vs AICAR: the difference explained

The comparison 5-amino-1MQ vs SLU-PP-332 vs AICAR revolves around three small molecules that all act on the energy metabolism of the cell, but at three entirely different points in the network. They are not peptides but small synthetic compounds, and that is precisely why they lend themselves to being studied side by side: the same outcome measure, three different entry points. Anyone using them within a single research design is in effect comparing three hypotheses about how mitochondrial capacity can be influenced.

Three points of action in one network

5-Amino-1MQ inhibits the enzyme NNMT and thereby intervenes in NAD homeostasis. SLU-PP-332 is an agonist of the ERR receptor family and drives the transcription of mitochondrial genes. AICAR mimics AMP and activates AMPK, the central energy sensor of the cell. All three pathways ultimately converge on mitochondrial biogenesis and fatty acid oxidation, but the order and the speed of events differ considerably.

5-Amino-1MQ: NNMT inhibition and the NAD pool

Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide and thereby removes it from the pathway leading to NAD. In adipose tissue, expression of this enzyme is elevated in obesity models. 5-Amino-1MQ is a small, cell-permeable inhibitor of NNMT; by blocking methylation, more nicotinamide remains available for NAD synthesis. Preclinical research looks mainly at adipocyte size and energy expenditure. The effect is indirect and unfolds over a longer period, because it runs via the size of a metabolite pool and not via direct receptor activation.

SLU-PP-332: transcriptional control via ERR

SLU-PP-332 is a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma. These are nuclear receptors that drive the transcriptional programme for oxidative metabolism — precisely the programme that endurance training also switches on. In mouse models, administration leads to a shift towards fatty acid oxidation and increased energy expenditure without any change in food intake. Because the effect runs via gene expression, there is a lead time of hours to days before the changes in mitochondrial proteins become measurable.

AICAR: AMPK activation through AMP mimicry

Inside the cell, AICAR is converted into ZMP, a molecule that closely resembles AMP. AMPK reads this as a signal of energy shortage and switches over to catabolic routes: glucose uptake up, fatty acid oxidation up, anabolic synthesis down. It is by far the oldest and best documented compound of the three, with literature going back to the nineteen-nineties. The effect sets in quickly but is short-lived, and AICAR is monitored under anti-doping policy, which explains the context of many publications.

The three compounds side by side

Speed versus durability of the effect

The practical distinction between the three lies mainly in the time scale. AICAR produces a fast, reversible switch and suits acute experiments with short measurement windows. SLU-PP-332 and 5-amino-1MQ alter the transcriptional programme and the availability of a cofactor respectively; both require longer exposure and longer observation. A four-hour experiment will give a clear signal with AICAR and next to nothing with the other two, which regularly leads to wrong conclusions in comparative work.

Why these three are not peptides

All three are small synthetic molecules, not amino acid chains. That has practical consequences: they are not sensitive to peptidases. They are usually dissolved as a powder in DMSO or an aqueous buffer, rather than reconstituted like a freeze-dried peptide. Solubility also differs considerably from one compound to another. For the comparison with peptide-based metabolic pathways, the metabolic peptides category is the starting point.

Combinations in research models

Because the three act at different levels, combination studies are mechanistically interesting. AMPK activation and ERR agonism both converge on PGC-1-alpha, which may turn out additive or, conversely, saturated. NNMT inhibition then builds on top of that via the NAD pool, which is needed as a cofactor for sirtuins. Anyone setting up such a design has to include a separate control for each arm; otherwise there is no telling which pathway carries the observed effect.

Handling and reconstitution in the laboratory

Store all three compounds dry, cool and dark. Unlike with peptides, bacteriostatic water is not always the right solvent here: check the solubility for each compound and, where necessary, use a small percentage of DMSO in the stock solution. Prepare stock solutions in small portions and avoid repeated freezing and thawing. Our reconstitution guide describes the general procedure; the concentration calculation works identically.

Quality & purity

With small molecules, identity confirmation by mass spectrometry is at least as important as with peptides, because related synthesis products cannot be told apart by appearance. Every batch we supply comes with a certificate of analysis covering HPLC purity and mass spectrometry, independently verified by an external laboratory. Why we are strict about this is explained in why we rejected a batch.

Frequently asked questions about 5-amino-1MQ, SLU-PP-332 and AICAR

Are these peptides?
No. All three are small synthetic molecules. They are often offered alongside peptides because the research fields overlap, but chemically they belong to a different class.

Which one works fastest?
AICAR. It activates AMPK directly via ZMP, which makes the effect measurable within minutes to hours. The other two work via gene expression or via a metabolite pool and need considerably longer.

Why is AICAR on the anti-doping list?
Because AMPK activation increased endurance capacity in animal studies without training. Those publications were the reason for anti-doping authorities to start monitoring the compound.

Is SLU-PP-332 the same as an exercise mimetic?
It is described that way in the literature because it mimics the transcriptional programme of endurance training. It is and remains a research compound at an early preclinical stage.

Can they be studied in combination?
Yes, and that is mechanistically interesting because the pathways converge on PGC-1-alpha and the NAD pool. In that case, do include a separate control arm for each compound.

Read more & research at Peplife

• Buy 5-Amino-1MQ (RUO)
• Buy SLU-PP-332 (RUO)
• Buy AICAR (RUO)
• All metabolic peptides
• 5-Amino-1MQ research
• SLU-PP-332 research
• AICAR research

Sources: PubChem — 5-Amino-1MQ · NNMT inhibition in adipose tissue, PubMed · SLU-PP-332 as an ERR agonist, ACS Chemical Biology · ERR agonism and oxidative metabolism, PMC · AICAR and AMPK activation, PMC · AMPK as an energy sensor, PubMed

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.